Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults

The inactivatedsevere acute respiratory syndrome coronavirus 2 vaccine (CoronaVac) has been the principal vaccine used in Chile’s prebooster immunization campaign. We compared major outcomes in 206 hospitalized vaccinated adults vs 507 unvaccinated adults (mid-2021). Individuals in the vaccinated gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolff, Marcelo, Gilabert, Margarita, Hernández, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963676/
https://www.ncbi.nlm.nih.gov/pubmed/35360196
http://dx.doi.org/10.1093/ofid/ofac122
Descripción
Sumario:The inactivatedsevere acute respiratory syndrome coronavirus 2 vaccine (CoronaVac) has been the principal vaccine used in Chile’s prebooster immunization campaign. We compared major outcomes in 206 hospitalized vaccinated adults vs 507 unvaccinated adults (mid-2021). Individuals in the vaccinated group were much older, required less critical care, had lower mortality (adjusted by age), and had shorter hospitalization than those in the unvaccinated group. Benefits were most pronounced in those ≥60years of age.

Ejemplares similares